Rutgers Health/New Jersey Medical School
Pathology residency · Newark, NJ · Program website
This program's roster hasn't been collected yet, so there's no list of its own faculty and papers. Below is Rutgers Health's research in pathology, which the program shares with other departments and affiliated hospitals.
About Rutgers Healthinstitution-wide pathology research
Pathology publications from Rutgers Health + Rutgers New Jersey Medical School and affiliated institutions, since 2022. Updated 2026-11-06; refreshed daily.
81
works per year
12th of 65 pathology residency programs
+9.7%
2-year growth
30th of 65 pathology residency programs
19.4%
in top 10% of field (works before 2025)
28th of 56 pathology residency programs
43.2%
cited above world average
22nd of 56 pathology residency programs
Works per year · * 2026 so far
Pathology and Forensic Medicine · 392
Pathology research topics at Rutgers Health
Papers in the window; each links to the list on OpenAlex.
Most cited at Rutgers Health since 2024
All pathology papers there on OpenAlex
- Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapyJennifer Leigh Crombie et al. · Blood · 2024 · PubMed · cited 159
- Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapiesLaurie Helen Sehn et al. · Blood · 2024 · PubMed · cited 102
- An Update of a Clinical Practice Guideline for the Management of Patients With Acute Spinal Cord Injury: Recommendations on the Role and Timing of Decompressive SurgeryMichael George Fehlings et al. · Global Spine Journal · 2024 · PubMed · cited 80
- Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell LymphomaFranck Morschhauser et al. · Journal of Clinical Oncology · 2025 · PubMed · cited 56
- Alcohol-Associated Liver Disease MortalityChun‐Wei Pan et al. · JAMA Network Open · 2025 · PubMed · cited 54
- Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamabTaylor Brooks et al. · Blood · 2025 · PubMed · cited 45
- Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826Sarah C. Rutherford et al. · Journal of Clinical Oncology · 2025 · PubMed · cited 36
- Fatigue in multiple sclerosis: can we measure it and can we treat it?John DeLuca · Journal of Neurology · 2024 · PubMed · cited 30
- Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphomaJurriaan Brouwer‐Visser et al. · Journal for ImmunoTherapy of Cancer · 2024 · PubMed · cited 29
- Spinal Cord Transcutaneous Stimulation in Cervical Spinal Cord Injury: A Review Examining Upper Extremity Neuromotor Control, Recovery Mechanisms, and Future DirectionsGoutam Singh et al. · Journal of Neurotrauma · 2024 · PubMed · cited 25